Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry) [PDF]
, 2023 BACKGROUND: Selexipag is an oral prostacyclin receptor agonist, indicated for pulmonary arterial hypertension to delay disease progression and reduce the risk of pulmonary arterial hypertension-related hospitalization. SelexiPag: tHe usErs dRug rEgistry (
Anna R. Hemnes +21 more
core +1 more source
Clinical evaluation of drug?drug interactions between the cytochrome P450 substrates selexipag and clopidogrel in Japanese volunteers [PDF]
, 2021 Aims: The strong cytochrome P450 (CYP) 2C8 inhibitor gemfibrozil has been demonstrated to increase the area under the plasma concentration-time curve from 0 to infinity (AUC0?∞) of ACT-333679, an active metabolite of selexipag, by 11-fold.
Katayama, Naoki +9 more
core +2 more sources
The Evolving Landscape of Pulmonary Hypertension Treatment: From Vasodilation to Disease Modification. [PDF]
Clin Transl SciABSTRACT Pulmonary hypertension (PH) is a complex disorder associated with significant morbidity and mortality. PH is characterized by an elevated pulmonary vascular load, leading to right ventricular dysfunction and remodeling, with right heart failure and premature death if left untreated.
Ayalasomayajula S +8 more
europepmc +2 more sources
Selexipag for the treatment of pulmonary arterial hypertension
, 2021 Introduction: Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH.
Wacker, J. +7 more
core +1 more source
Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series [PDF]
, 2020 BackgroundThere are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use.
Mahadevan, Vaikom S +2 more
core +1 more source
Respiratory Medicine Case Reports, 2022 The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective.
Mizuki Momoi +7 more
doaj +1 more source
Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics
Frontiers in Medicine, 2021 High-altitude pulmonary hypertension (HAPH) is a complication arising from an inability to acclimatize to high altitude and is associated with high morbidity and mortality.
Xiang Xu +11 more
doaj +1 more source
, 2023 Objective: Adding selexipag to the combined treatment of endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitor (PDE5i) reduces the risk of clinical worsening events in patients with pulmonary arterial hypertension (PAH) but at a ...
Rong Zhang (44942) +15 more
core +1 more source
Кардиоваскулярная терапия и профилактика, 2021 We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due
E. A. Rezukhina +2 more
doaj +1 more source
Selexipag in pregnancy and pulmonary arterial hypertension
IHJ Cardiovascular Case Reports, 2023 Pregnancy poses a significant maternal and foetal risk in women with pulmonary arterial hypertension (PAH). With extremely limited treatment options available, we used Selexipag in addition to tadalafil in managing a pregnancy complicated by PAH ...
Sweta Mohanty +4 more
doaj +1 more source